Open questions in autoimmunity: discussions from the 2013 Controversies in Rheumatology and Autoimmunity Meeting

BMC Medicine

Yehuda Shoenfeld²  Carlo Selmi¹ 

[1] Division of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Milan, Italy;Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer 52621, Israel Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Israel

关键词: Ultrasonography;    Rheumatoid arthritis;    microRNA;    DNA methylation;    Cardiovascular system;    Atherosclerosis;    Anti-nuclear antibodies;   

Others  :  854939
DOI  :  10.1186/1741-7015-12-50

 received in 2014-03-07, accepted in 2014-03-07,  发布年份 2014

【 摘 要 】

The recent CORA (Controversies in Rheumatology and Autoimmunity) meeting held in 2013 represented a unique opportunity for rheumatologists to address several topics. Among these, four topics include: (i) the role of epigenetic changes in the pathogenesis of rheumatoid arthritis (RA), as shown by studies in monozygotic twins; (ii) the cardiovascular and atherosclerotic risk in patients with RA treated with biologics; (iii) the use of new biomarkers for the diagnosis and follow-up of RA and other autoimmune diseases, as represented by the new automatic machines for anti-nuclear antibodies detection, or ultrasound imaging to follow RA progression; and (iv) the latest guidelines on how to use and manage biologic therapies in RA and other autoimmune diseases, such as lupus. In summary, we will herein present these topics of discussion and underline the conclusions obtained by rheumatologists during the 2013 CORA Meeting.

【 授权许可】

   
2014 Selmi and Shoenfeld; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Selmi C: Autoimmunity in 2012. Clin Rev Allergy Immunol 2013, 45:290-301.
• [2]Bogdanos DP, Smyk DS, Rigopoulou EI, Mytilinaiou MG, Heneghan MA, Selmi C, Gershwin ME: Twin studies in autoimmune disease: genetics, gender and environment. J Autoimmun 2012, 38:J156-J169.
• [3]Selmi C, Lu Q, Humble MC: Heritability versus the role of the environment in autoimmunity. J Autoimmun 2012, 39:249-252.
• [4]Lu Q: The critical importance of epigenetics in autoimmunity. J Autoimmun 2013, 41:1-5.
• [5]Costenbader KH, Gay S, Alarcon-Riquelme ME, Iaccarino L, Doria A: Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? Autoimmun Rev 2012, 11:604-609.
• [6]De Santis M, Selmi C: The therapeutic potential of epigenetics in autoimmune diseases. Clin Rev Allergy Immunol 2012, 42:92-101.
• [7]Liu Y, Li H, Xiao T, Lu Q: Epigenetics in immune-mediated pulmonary diseases. Clin Rev Allergy Immunol 2013, 45:314-330.
• [8]Luo Y, Wang Y, Wang Q, Xiao R, Lu Q: Systemic sclerosis: genetics and epigenetics. J Autoimmun 2013, 41:161-167.
• [9]Ngalamika O, Zhang Y, Yin H, Zhao M, Gershwin ME, Lu Q: Epigenetics, autoimmunity and hematologic malignancies: a comprehensive review. J Autoimmun 2012, 39:451-465.
• [10]Thabet Y, Canas F, Ghedira I, Youinou P, Mageed RA, Renaudineau Y: Altered patterns of epigenetic changes in systemic lupus erythematosus and auto-antibody production: is there a link? J Autoimmun 2012, 39:154-160.
• [11]Zhang Y, Zhao M, Sawalha AH, Richardson B, Lu Q: Impaired DNA methylation and its mechanisms in CD4(+)T cells of systemic lupus erythematosus. J Autoimmun 2013, 41:92-99.
• [12]Glant TT, Mikecz K, Rauch TA: Epigenetics in the pathogenesis of rheumatoid arthritis. BMC Med 2014, 12:35. BioMed Central Full Text
• [13]Coit P, Jeffries M, Altorok N, Dozmorov MG, Koelsch KA, Wren JD, Merrill JT, McCune WJ, Sawalha AH: Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naive CD4+ T cells from lupus patients. J Autoimmun 2013, 43:78-84.
• [14]Pengo V, Banzato A, Denas G, Jose SP, Bison E, Hoxha A, Ruffatti A: Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev 2013, 12:832-834.
• [15]Priori R, Scrivo R, Brandt J, Valerio M, Casadei L, Valesini G, Manetti C: Metabolomics in rheumatic diseases: the potential of an emerging methodology for improved patient diagnosis, prognosis, and treatment efficacy. Autoimmun Rev 2013, 12:1022-1030.
• [16]Rossi D, Russo A, Manna E, Binello G, Baldovino S, Sciascia S, Roccatello D: The role of nail-videocapillaroscopy in early diagnosis of scleroderma. Autoimmun Rev 2013, 12:821-825.
• [17]Matsuura E, Lopez LR, Shoenfeld Y, Ames PR: β2-glycoprotein I and oxidative inflammation in early atherogenesis: a progression from innate to adaptive immunity? Autoimmun Rev 2012, 12:241-249.
• [18]Siegel D, Devaraj S, Mitra A, Raychaudhuri SP, Raychaudhuri SK, Jialal I: Inflammation, atherosclerosis, and psoriasis. Clin Rev Allergy Immunol 2013, 44:194-204.
• [19]Singh RP, Massachi I, Manickavel S, Singh S, Rao NP, Hasan S, Mc Curdy DK, Sharma S, Wong D, Hahn BH, Rehimi H: The role of miRNA in inflammation and autoimmunity. Autoimmun Rev 2013, 12:1160-1165.
• [20]Iborra M, Bernuzzi F, Invernizzi P, Danese S: MicroRNAs in autoimmunity and inflammatory bowel disease: crucial regulators in immune response. Autoimmun Rev 2012, 11:305-314.
• [21]Saito Y, Saito H, Liang G, Friedman JM: Epigenetic alterations and microRNA misexpression in cancer and autoimmune diseases: a critical review. Clin Rev Allergy Immunolin press
• [22]Ando Y, Yang GX, Kenny TP, Kawata K, Zhang W, Huang W, Leung PS, Lian ZX, Okazaki K, Ansari AA, He XS, Invernizzi P, Ridgway WM, Lu Q, Gershwin ME: Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-beta receptor type II mouse. J Autoimmun 2013, 41:111-119.
• [23]Hahn BH, Grossman J, Chen W, McMahon M: The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 2007, 28:69-75.
• [24]Soltesz P, Kerekes G, Der H, Szucs G, Szanto S, Kiss E, Bodolay E, Zeher M, Timar O, Szodoray P, Szegedi G, Szekanecz Z: Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment. Autoimmun Rev 2011, 10:416-425.
• [25]Pengo V, Ruiz-Irastorza G, Denas G, Andreoli L, Khamashta M, Tincani A: High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. Autoimmun Rev 2012, 11:577-580.
• [26]Matsuura E, Atzeni F, Sarzi-Puttini P, Turiel M, Lopez LR, Nurmohamed MT: Is atherosclerosis an autoimmune disease? BMC Med 2014, 12:47.
• [27]Doria A, Dayer JM, Punzi L: Autoinflammatory diseases: how to put the fire inside the body out? Autoimmun Rev 2012, 12:1-4.
• [28]Rigante D: The fresco of autoinflammatory diseases from the pediatric perspective. Autoimmun Rev 2012, 11:348-356.
• [29]Zen M, Gatto M, Domeneghetti M, Palma L, Borella E, Iaccarino L, Punzi L, Doria A: Clinical guidelines and definitions of autoinflammatory diseases: contrasts and comparisons with autoimmunity-a comprehensive review. Clin Rev Allergy Immunol 2013, 45:227-235.
• [30]Chamorro AJ, Marcos M, Miron-Canelo JA, Cervera R, Espinosa G: Val247Leu beta2-glycoprotein-I allelic variant is associated with antiphospholipid syndrome: systematic review and meta-analysis. Autoimmun Rev 2012, 11:705-712.
• [31]de la Torre YM, Pregnolato F, D'Amelio F, Grossi C, Di Simone N, Pasqualini F, Nebuloni M, Chen P, Pierangeli S, Bassani N, Ambrogi F, Borghi MO, Vecchi A, Locati M, Meroni PL: Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the beta2 glycoprotein I phospholipid-binding site, Implications for human fetal loss. J Autoimmun 2012, 38:J209-J215.
• [32]Mahler M, Norman GL, Meroni PL, Khamashta M: Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev 2012, 12:313-317.
• [33]Tozzoli R, Villalta D: Autoantibody profiling of patients with antiphospholipid syndrome using an automated multiplexed immunoassay system. Autoimmun Rev 2014, 13:59-63.
• [34]Conrad K, Roggenbuck D, Reinhold D, Sack U: Autoantibody diagnostics in clinical practice. Autoimmun Rev 2012, 11:207-211.
• [35]Villalta D, Imbastaro T, Di Giovanni S, Lauriti C, Gabini M, Turi MC, Bizzaro N: Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun Rev 2012, 12:114-120.
• [36]Damjanov N, Nurmohamed MT, Szekanecz Z: Biologics, cardiovascular effects and cancer. BMC Med 2014, 12:48.
• [37]van Sijl AM, Peters MJ, Knol DL, de Vet RH, Sattar N, Dijkmans BA, Smulders YM, Nurmohamed MT: The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum 2011, 41:393-400.
• [38]van Vollenhoven RF, Nagy G, Tak PP: Early start and stop of biologics: has the time come? BMC Med 2014, 12:25. BioMed Central Full Text
• [39]Gatto M, Kiss E, Naparstek Y, Doria A: In/Off label use of biologic therapy in systemic lupus erythematosus. BMC Med 2014, 12:30. BioMed Central Full Text
• [40]Mocsai A, Kovacs L, Gergely P: What is the future of targeted therapy in rheumatology: biologics or small molecules? BMC Med 2014, 12:43. BioMed Central Full Text
• [41]Meroni PL, Bizzaro N, Cavazzana I, Borghi MO, Tincani A: Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations. BMC Med 2014, 12:38. BioMed Central Full Text
• [42]Melegari A, Bonaguri C, Russo A, Luisita B, Trenti T, Lippi G: A comparative study on the reliability of an automated system for the evaluation of cell-based indirect immunofluorescence. Autoimmun Rev 2012, 11:713-716.
• [43]Bizzaro N, Antico A, Platzgummer S, Tonutti E, Bassetti D, Pesente F, Tozzoli R, Tampoia M, Villalta D, Study Group on Autoimmune Diseases of the Italian Society of Laboratory Medicine I: Automated antinuclear immunofluorescence antibody screening: a comparative study of six computer-aided diagnostic systems. Autoimmun Rev 2014, 13:292-298.
• [44]Koenig M, Dieude M, Senecal JL: Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. Autoimmun Rev 2008, 7:588-593.
• [45]Moinzadeh P, Nihtyanova SI, Howell K, Ong VH, Denton CP: Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma. Clin Rev Allergy Immunol 2012, 43:249-255.
• [46]Meroni PL, Schur PH: ANA screening: an old test with new recommendations. Ann Rheum Dis 2010, 69:1420-1422.
• [47]Senolt L, Grassi W, Szodoray P: Laboratory biomarkers or imaging in the diagnostics of arthritides? BMC Med 2014, 12:49.
• [48]Shi J, van Veelen PA, Mahler M, Janssen GM, Drijfhout JW, Huizinga TW, Toes RE, Trouw LA: Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun Rev 2014, 13:225-230.
• [49]Acharya NK, Nagele EP, Han M, Coretti NJ, DeMarshall C, Kosciuk MC, Boulos PA, Nagele RG: Neuronal PAD4 expression and protein citrullination: possible role in production of autoantibodies associated with neurodegenerative disease. J Autoimmun 2012, 38:369-380.
• [50]Auger I, Charpin C, Balandraud N, Martin M, Roudier J: Autoantibodies to PAD4 and BRAF in rheumatoid arthritis. Autoimmun Rev 2012, 11:801-803.